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ABSTRACT
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Background:
A major safety concern in elderly population is the use of inappropriate medication. Owing to agingassociated with anatomic and physiologic changes, pharmacokinetic and pharmacodynamics of drugs are
prone to alter in these elderlies. Inappropriate drug prescribing and polypharmacy in this population elevates
the risk of adverse drug reactions.

Objectives:
To assess the prevalence and factors influencing Potentially Inappropriate Medication (PIM) use in elderly
patients according to updated Beers Criteria.

Methodology:
A retrospective observational study was carried out. Case records of 580 patients aged 65 years and above
were reviewed. Every case record was identified for at least one PIM based on the American Geriatric
Society 2019 Updated Beers Criteria for PIM use in elderly patients. Analysis of collected data was done
using Statistical Package for Social Sciences (SPSS) software.

Results:
A total of 580 elderly general medicine patients were reviewed amongst them, 301 were identified as test
group with the age of mean 73.7±6.4 years and 101 patients as control group with the age of mean 70.5±5.5
years. Most of the study population were males 59.1% in test and 63.4% in control groups. The prevalence
of PIMs to be used with caution were 54% and PIMs to be avoided were 45% the most prescribed PIMs
were aspirin (23.51%), diuretics (15.56%), long acting sulphonylureas (12.75%) and Proton Pump
inhibitors(PPIs) (11.92%). Increasing age polypharmacy, number of drugs in medication history, certain
Chronic diseases were associated with high probability of PIM’s use among elderly patients. Risk of
developing serious, moderate drug-drug interactions (DDIs) was high in elderly patients with PIMs.

Conclusion:
Potentially inappropriate medication use poses a sizable health safety hazard in elderly patients. After
evaluating the potentially inappropriate medications of elderly patients using the updated Beers Criteria
2019.Prevalence of PIMs that should be used with caution (54%) was found to be highest followed by PIMs
to be avoided (45%) and recommendation for reduce dose to be (1%) .Age, gender, comorbidities, and
polypharmacy were identified as risk factors leading to PIM use. It was also observed that patients with
PIMs are at a higher risk of developing DDIs. A significant increase in the older population and the need to
reduce preventable harm calls for more multidisciplinary strategies to account for the use of high-risk
medications. Prescribers can use this data to determine patients at a higher risk for PIMs and be attentive to

8

them while prescribing. Continuous medication and prescription review done by a clinical pharmacist can
aid in reducing the occurrence of PIMs.
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INTRODUCTION
Potentially inappropriate medication (PIM) is a drug or drug class which should be avoided in patients aged
65years or above (geriatrics) as their risk of causing potential adverse event outweighs their clinical benefit
[1]. Due to advancing age, multiple chronic problems and comorbidities can result in complex therapeutic
regimens, which in turn lead to polypharmacy [2]. Increased number of drugs prescribed leads to an
increased prevalence of interactions between the drugs. Higher risk of use of PIMs is attributed to the direct
independent relation with increased number of medications. [3].
Multiple studies have identified a high prevalence of PIMs in older adults [4]. Geriatrics account for 4.8% of
the total population in India according to the 2011 Census. With the availability of better health care
facilities and an increase in life expectancy, the elderly population has increased from the year 1991 to 2011.
Increased life expectancy poses a need for better patient care in all sets of population, particularly in
vulnerable populations like geriatrics. In elderly people, medication-related problems increase due to
increasing age-dependent physiological changes that affect the pharmacokinetics and pharmacodynamics of
the drugs [5].
A research carried out in The USA revealed that unplanned hospitalization in older adults is majorly due to
adverse drug reactions (ADRs). These ADRs are manageable and preventable with further studies.
Implementation of population-based results, while also stressing on the need for reducing inappropriate
prescribing can certainly help prevent these ADRs. [6].
With rising PIM use in geriatrics, American Geriatric Society (AGS) Beers Criteria 2019, which is an
explicit list of PIMs, supposed to be typically best avoided in older adults aged 65 years has the potential to
become a mandatory tool in providing better health care services for the elderly [7].
It is known amongst health care professionals as AGS - Beers Criteria® 2019. Research on 2012 publish of
Beers Criteria documented that at least 40% of patients had minimum one PIM whereas, approximately 30%
PIMS were seen according to the 2003 publishing of the same. [8]
Another study from the Netherlands concluded that more than half of the participants with a history of
cardiovascular disease (CVD) or/and cerebrovascular disease (CVA) had at least one PIM. About 40% of
the test participants with identified PIMs posed a potential risk of Major Adverse Cardiac and
cerebrovascular events [9].
Geriatrician Mark H. Beers, with a panel of his expert colleagues, formulated this criterion in 1991. In 2011
after the demise of Dr.Beers, the criterion was transferred to the American Geriatric Society, which is a nonprofit organization working towards providing better geriatric care. The development of this criterion was
11

intended to provide an efficient and comprehensive tool to help assess the prescribing quality in older adults
despite their debility and demographics.
A team of 13 interdisciplinary experts reviewed more than 1,400 research studies and clinical trials between
2017 and the last Beers Criteria update in 2015 on geriatric care and pharmacotherapy to formulate Beers
Criteria 2019 using Delphi’s method [10].
Drugs included in the Beers list are classified under three brackets: 1) drugs to be avoided in elderly, 2)
drugs that overshoot a maximum daily dose 3) drugs to be avoided in the presence of specific comorbidities.
In specific cases, these tabulated medications might be suitable for specified off label use. This is also a
helpful tool in drug utilization studies.
70 changes were released in this update. Addition of 30 drugs or drug classes to be avoided in old people
along-with 40 drug or drug classes to be used with caution or avoid when someone lives with diseases or
conditions. These amendments also included outright removal of 25 previously identified potentially
inappropriate medications. Similarly, several other drugs were re-categorized with the help of stronger
evidence [10].
Now, AGS Beers Criteria 2019 comprises five lists of nearly 100 medications and classes of medicines that
are supposed to be avoided or used with caution in the older adult population. It offers itself as a broad tool
to help the clinicians, nurses, and caregivers have a better chance at geriatric healthcare [10].
Critical care units serve a pivotal role in patient care through lifesaving and life-preserving treatments.
Assessing a patient’s health status and carrying out a medication evaluation to alter the medication regimen
to provide safer alternatives for older adults is important. Beers Criteria is not a clinical rule; instead, it is a
clinical guideline with recommendations to support a clinician’s judgment of the therapy given to the
patient. Keeping in mind the safety and efficacy of geriatric prescriptions the Beers Criteria is updated to
keep up with the best practices in the present world scenarios like avoiding prolonged use of PPIs, nonbenzodiazepines, benzodiazepine receptor agonist, hypnotics regardless of the duration of exposure. Tables
with updated information on the list of drugs to avoid or reduce dosage based on kidney function along with
updated tables of DDIs are provided which add to its benefits [11].
An average of at least four drugs is seen which goes up to 10 and more than 10 in some cases. It highlights
the need for periodic assessment of prescriptions to minimize polypharmacy which has been identified as a
sizable factor leading to high inappropriate medication use [12]. Moreover, there is a need to subsume Beers
Criteria into the electronic prescribing system to forewarn the medical service providers at the time of
prescribing, in turn, enabling them to mitigate potential harm [13]. A high number of patients presented with
acute ailments end up taking PIMs at discharge or during admission. This high prevalence appears to
increase by nearly 20% after hospitalization. Even after the PIMs presented in the prescriptions on
admission were emended, 45% of these patients received other PIMs during the hospital stay. Given the
12

harmful effects that these PIMs might lead to, it is important to address this problem and incorporate this
tool for providing better geriatric care. [14] It also highlights the need for practicing geriatrics as a specialty
in our country. (14)
To the best of our knowledge, this new criterion has not been employed in any studies in the country so far.
Therefore, we have carried out a study based on elderly patients in a tertiary care hospital of Karnataka to
estimate prevalence of PIM use, factors influencing their use and impact of PIMs leading to drug-drug
interaction using updated AGS Beers Criteria 2019

13
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NEED FOR THE STUDY
Older adults differ from younger adults in several ways that put them at risk of harm by drug interactions
and ADR. Aging is often being accompanied by chronic diseases, comorbidities, disabilities, and social
isolation leading older adults to have more illnesses. Hence, geriatrics are most often the main group that
needs to get hospitalized for their illnesses. It is not surprising that aging progressively increases the number
of drugs taken by each elderly patient. [10] Factors like aging, female gender, polypharmacy, multiple
prescribers, poor health quality, chronic diseases like hypertension, diabetes, CVD, CVA and depression
were seen to be associated with higher risk for PIM use.[4]
Thus, the need to pre-evaluate elderly prescriptions at the time of prescribing in acute, ambulatory, or
institutional settings, in the case of polypharmacy and patients with multiple comorbidities is warranted.
PIM use has become a worldwide concern among geriatrics. The use of PIMs leads to the risk of medication
misadventure in geriatrics. AGS Updated Beers Criteria 2019 is the most recently updated criteria that is
nowadays being widely used across the globe to assess and evaluate PIM use in geriatrics. Beer Criteria
provide a comprehensive list of probable PIMs with proper rationales for their off label uses if any. In India
however, a couple of studies have highlighted the contribution of polypharmacy and drug interactions
among geriatrics.[10]. No systematic study has been documented examining PIMs prescribing done
previously among elderly patients in this locality. Hence the main objective of this study was to assess
prevalence of PIM use and factors associated with their use in elderly patients using the AGS 2019 Updated
Beers Criteria.
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OBJECTIVES
•
•

To assess the prevalence of PIM use in elderly patients according to updated Beers Criteria.
To assess factors influencing PIM use in elderly patients according to updated AGS Beers Criteria
2019.
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METHODOLOGY
An observational study was retrospectively conducted in a tertiary care hospital located in Karnataka, South
India. Ethical Clearance from Institutional Ethics Committee, MAHE (IEC-562/2019) was obtained before
the start of the study. Patients of both genders aged 65 years or older and admitted under the Department of
Medicine between June 2018 -June 2019. A total of 580 files were reviewed and 402 files were considered
for the study. Out of 402 files subjects with at least one PIM (according to AGS 2019 Updated Beers
Criteria) in their discharge prescription were included as test group. Subjects with no PIMs in the discharge
prescription were included as control group. Patients discharged against medical advice and expired were
excluded. PIM was identified for each patient from the medical record and classified according to 2019 AGS
Updated Beers Criteria. These PIMs were categorized according to their recommendations as, avoid (avoid
using the medication or medication class) caution (medication or medication classes to be regularly
monitored), and reduce dose (medications for which a dose reduction is needed if identified as PIM).
Demographical details like age, gender, weight, height, BMI, and personal history were also obtained.
Presence of any medication or medical history related to the pre-hospitalization period, complaints present
during the admission and the diagnosis with comorbidities were recorded. The brand name, generic name,
strength, dose, frequency, and duration of the discharge medications were also recorded. Patient’s serum
creatinine was noted and creatinine clearance was calculated in patients using the age-adjusted standard
formula: [133-(0.64*age)] for males and 93% of the value for females [19], and for the patients with kidney
diseases creatinine clearance (CrCl) was taken from the medical record. Medications prescribed at the time
of discharge were retrospectively screened for potential DDIs, using IBM Micromedex and Medscape. The
interactions were divided into serious, moderate and, minor according to their indicated severity. Drugdisease interactions were also studied according to the Beers list.
A pre-designed case report form (CRF) was used to enter the captured data. Outcome measures were
categorized the primary outcome: prevalence of inappropriate medication uses in patients above or equals to
65years of age secondary outcomes: factors influencing inappropriate medication use.
Statistical Package for the social sciences version 22.0 was used for data entry and statistical analysis.
Continuous data were analyzed using mean ± SD and categorical variables were analyzed using frequency
and percentage. Factors associated with the PIM use(outcome), to predict the risk of serious, moderate, and
minor drug-drug interactions(outcome) in patients with PIMs were evaluated by performing Binary logistic
regression analysis.
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RESULTS
DEMOGRAPHICS OF THE STUDY POPULATION:
Medical charts of 580 patients were reviewed. 178 patients unfit according to the study criteria were
excluded. Amongst them 301were identified as the test group (≥1 PIMs) and 101 Patients were identified as
the control group (no PIMs). The mean age of the study population was found to be 73.7±6.4 years in test,
70.5±5.5 years in control. Most patients were male in the test population. The test group was found to have
history of medication use ≥3 (53.8%) as shown in Table 1.

Variable
Age
Gender

Female
Male
Number of Drugs in medication history
No. of drugs in 0
medication history
1
2
≥3

Test
73.7±6.4 years
123(40.9%)
178(59.1%)

Control
70.5±5.5 years
37(36.6%)
64(63.4%)

76(25.2%)
32(10.6%)
31(10.3%)
162(53.8%)

52(51.5%)
18(17.8%)
13(12.9%)
18(17.9%)

Table 1. Patient demographics

Majority of the test population had three or more comorbidities, whereas in control mostly one comorbidity
was prevalent. Hypertension followed by type 2 diabetes mellitus were found to be common as shown in
Table 2.

VARIABLE
Number of Comorbidities

TEST
0
1
2
≥3

25(8.3%)
53(17.6%)
93(30.9%)
130(43.2%)
225(74.8%)
181(60.1%)
28(9.3%)
40(13.3%)
106(35.2%)
36(12.0%)
29(9.6%)
13(4.3%)
31(10.3%)

CONTROL
29(28.7%)
36(35.6%)
22(21.8%)
14(13.9%)
47(46.5%)
26(25.7)
13(12.9%)
8(7.9%)
11(10.9%)
7(6.9%)
7(6.9%)
2(2.0%)

Hypertension
Type 2 Diabetes Mellitus
Asthma
Chronic Obstructive Lung Disease (COPD)
Cardiovascular Disease
Cerebrovascular Disease
Hypothyroidism
Kidney Disease
Acute Kidney Disease
Chronic Kidney Disease
Acute Liver Disease
1(1.0%)
Liver Disease
Chronic Liver Disease
9(3.0%)
3(3.0%)
Table 2. Frequency and percentage of comorbidities.
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PREVALENCE OF PIMS:
Our study found a high prevalence of PIMs to be used with Caution (n=348)(54%) than the PIMs to be
Avoided (n= 291)(45%) and recommendation to prescribe drug at Reduce dose (n= 9)(1%) as highlighted in
Fig 1.
Reduce dose
1%

Avoid:
45%
Caution:
54%

Fig 1. Prevalence of PIMs
The four most prescribed PIMs in our study population were found to be aspirin, diuretics (furosemide,
torsemide, spironolactone), long-acting sulphonylureas (glimepiride, glibenclamide), proton pump inhibitors
(PPIs) as per AGS 2019 updated Beers Criteria (Table 3).

DRUGS
Aspirin
Diuretics
Long acting sulphonylureas
PPIs
Tramadol
Prazosin
Levetiracetam
Benzodiazepines
Dextromethorphan
Dicyclomine
Non-steroidal anti-inflammatory drugs (NSAIDs)
Digoxin
Antipsychotics
Anticholinergics
Selective Serotonin Reuptake Inhibitors (SSRI)
Pregabalin
Serotonin Norepinephrine Reuptake Inhibitors (SNRI)

PERCENTAGE
23.51%
15.56%
12.75%
11.92%
4.97%
2.81%
0.50%
4.47%
1.99%
0.17%
0.83%
0.50%
4.64%
3.48%
1.82%
0.66%
0.17%
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Gabapentin
Dabigatran
Amiodarone
Ranitidine
Non-Dihydropyridines
Nitrofurantoin
Anti-Parkinson’s
Barbiturates
Mineral Oil
Mirtazapine
Antiepileptics

0.17%
1.66%
1.49%
0.17%
0.17%
0.33%
0.17%
0.50%
3.15%
1.16%
0.17%

Duloxetine

0.17%
Table 3. Percentage of PIMs

Comparison of gender and PIMs: Comparing Gender with PIMs (only in Test group), out of 178 males, 67
were observed to have one PIM, 62 had 2 PIMs and 49 had 3 or more PIMs. Similarly, out of 123 females,
41 were observed to have one PIM. (Fig 2).

62

49

52

60
50

41

40
30

Number of patients

70

67

80

30

20
10
0
1

2

≥3

Number of pims
Male

Female

Fig 2. Comparison of Gender and Number of PIMs
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Comparison of co-morbidities and PIMs: Comparing the number of comorbidities with the number of PIMs,
out of 54 patients with zero comorbidities, 29 had zero PIMs. Out of 89 patients who had one comorbidity,
36 had zero PIMs. Out of 115 patients with 2 comorbidities 39 had one PIM. Out of 144 patients with > 3
comorbidities, 51 had ≥3 PIMs as highlighted in Fig3.

60

Number of patients

51
50

40
30

42

39

36

37

29

27

27

22

20

17

20

16

14

12
10

7

6

0
0

1

≥3

2

Number of comorbidities
0 PIMs

1 PIMs

2 PIMs

≥3 PIMs

Fig 3. Comparison of PIMs and Comorbidities
Comparison of the number of drugs in medication history and PIMs: As highlighted in Fig 4 while
comparing the number of drugs in medication history and PIMs 76 patients with 0-3 drugs in medication
history had single PIM usage,33 patients with 4 to 7 drugs in medication history prescribed with two PIMs
and 3 PIMs were mostly observed in patients with more than 7 drugs in medication history.
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Fig 4. Comparison of number of drugs in medication history and PIMs
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Comparison of the total number of discharge drugs and PIMs: The total number of drugs prescribed at
discharge were grouped as 1-5drugs,6-10drugs and ≥10 drugs and PIMs as 0(control),1,2,3 and ≥4 as
depicted below in fig 5. Out of 93 patients prescribed with 1-5drugs, 55 were observed to have no PIMs. Out
of 119 patients prescribed with >10 drugs, zero PIMs were seen in only 8 patients and mostly have ≥4 PIMs.
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Fig 5. Comparison of Number of Drugs in discharge and PIMs in both Test and Control
Comparison of age and PIMs: On comparing age with the number of PIMs it was observed that elderly
patients of age 85 years and above had a greater number of PIMs (≥3). Zero PIMs were more prevalent in
the age group between 65 to 69 as depicted in Fig 6.
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Fig 6. Comparison of age and PIMs
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Drug-drug interaction in test and control: When compared for drug interactions in test and control, serious

SERIOUS

MODERAT E

MINOR

3

0

2

12

22

28

Number of patients

506

535

and moderate drug interactions were found to be very high in test population as depicted in Fig.7.

CONT RAINDICAT ED

Number of drug-drug interactions
Control

Test

Fig 7. Comparison of drug-drug interactions in test and control

RISK FACTORS ASSOCIATED WITH PIM USE IN LOGISTIC REGRESSION ANALYSIS
On performing regression analysis, PIM use was found to be more likely in elderly patients. Male patients
were at fewer odds of having PIMs compared to females. Elderly patients with a history of ≥3 drugs and
polypharmacy were observed to have a significant risk of having PIMs. It was also observed that elderly
patients with hypertension, type2 diabetes mellitus, cardiovascular diseases, cerebrovascular diseases, and
acute kidney disease were at more odds to have PIMs in contrast to patients with asthma, Chronic
Obstructive Lung Disease (COPD), thyroid disease and chronic liver disease. An increase in the number of
comorbidities is also seen to be associated with a significant prevalence of PIMs. The Odds ratio (OR), 95%
Confidence Interval (95% CI) and p-value are depicted in Table.4.

VARIABLE

OR (95%CI)

p-value

Age
65yrs-69yrs(n=143)
70yrs-74yrs(n=111)

1
3.157 (1.533-6.502)

NA
0.002 *

75yrs-79yrs(n=76)

4.983 (1.949-12.744)

0.001 *

>80yrs (72)

4.088 (1.547-10.804)

0.005 *

Gender
Male (242)
Female (160)
Hypertensive

0.671 (0.360-1.252)
1

0.21
NA
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Yes(n=272)

1.135 (0.372-3.464)

0.824

No(n=130)
Type 2 Diabetes Mellitus
Yes(n=207)
No (n=195)
Acute kidney disease

1

NA

1.830 (0.641-5.221)
1

0.259
NA

Yes(n=15)

2.250 (0.264-19.180)

0.458

No(n=387)
Asthma
Yes(n=41)
No(n=361)
Cardiovascular
Yes(n=117)
No(n=285)
COPD
Yes(n=48)
No(n=354)
Thyroid disease
Yes(n=36)
No (n=366)
Chronic Liver disease
Yes (n=12)
No (n=390)
Cerebrovascular disease
Yes(n=43)
No (n=359)
Medication history
0 Drugs(n=128)
1 Drug(n=50)
2 Drugs(n=44)
≥3 Drugs(n=180)
Number of Comorbidities
0(n=54)
1(n=89)
2(n=115)

1

NA

0.326 (0.091-1.166)
1

0.085
NA

1.225 (0.417-3.594)
1

0.712
NA

0.870 (0.243-3.120)
1

0.831
NA

0.744 (0.187-2.955)
1

0.674
NA

0.746 (0.121-4.603)
1

0.752
NA

1.873 (0.482-7.271)
1

0.365
NA

1
1.248 (0.529-2.945)
1.380 (0.542-3.511)
2.836 (1.262-6.373)

NA
0.613
0.499
0.012 *

1
0.917 (0.276-3.053)
1.399 (0.214-9.124)

NA
0.888
0.726

≥3(n=144)

1.579 (0.094-26.488)

0.751

Number of drugs prescribed at discharge
0-3 drugs (n=32)
1

NA

4-7 drugs(n=110)

5.988 (1.940-18.487)

0.002 *

>7 drugs(n=260)

31.875 (9.786-103.822)

0.000 *

*p-value<0.05, CI-Confidence Interval, >3 drugs prescribed at discharge defined as polypharmacy

Table.no.4 Regression analysis for risk factors
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DRUG-DRUG INTERACTIONS :
On regression analysis, the test group was observed to be at more odds to develop Serious and moderate
drug-drug interactions (DDIs). The Odds ratio, 95% Confidence Interval, and p-value are depicted in Tables
5,6 and 7 for Serious DDIs, Moderate DDIs, and Minor DDIs, respectively.

Variable

OR (CI 95%)

p-value

Test group
(n=301)

19.069(8.92940.725)

0.000

Control group
(n=101)

1

NA

Table.No5 Predicting the risk of serious drug-drug interactions in patients prescribed with PIMs

Variable

OR (CI 95%)

p-value

Test group
(n=301)

11.502(6.031-21.937)

0.000

Control group
(n=101)

1

NA

Table.No6 Predicting the risk of moderate drug-drug interactions in patients prescribed with PIMs

Variable

OR (CI 95%)

p-value

Test group
(n=301)

4.289(0.995-18.479)

0.051

Control group
(n=101)

1

NA

Table.No7 Predicting the risk of minor drug-drug interactions in patients prescribed with PIMs
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DISCUSSION
In the elderly patients, age-dependent physiological changes of the drugs lead to an increase in medicationrelated problems due to changes in drug’s pharmacokinetics and pharmacodynamics. While observing the
demographics of the study population the mean age of the study population was found to be 73.7 ±6.4years
in the test, and 70.5±5.5 years in control. It was further grouped into 4 categories, 65-69, 70-74, 75-79,
≥80. Using binary logistic regression as the statistical method it was seen that patients aged between 65-69
years were at lesser odds of receiving a PIM than those falling in the other 3 higher categories. This suggests
that as the age increases the risk of having a PIM in the patient’s therapy also increases. Similarly, earlier
studies have also been successful in establishing an association between age and PIM use [21]. Due to
advancing age and deteriorating health status [4], there is an increase in predisposing factors that lead to
chronic diseases which act as comorbidities over a period making PIM use (including off label use) more
prominent.
On comparing Gender in the study population out of a total of 301 test population 178(59.1%) were male
and 123(40.9%) were female patients. Whereas in Control group males were 64(63.4%), and females were
37(36.6%). Male patients were observed to be higher in number in both Test and control. Male patients were
observed to have a lesser risk of having a PIM when compared to females with odds of 0.671 but statically
not significant as the p-value is 0.210. An earlier study from Brazil also associated the male gender with
fewer PIMs. This difference may be attributed to likeliness of women to visit the doctor and express their
problems over men. [16].

Regarding the comorbidities, many studies suggest that PIMs are strongly associated with several
comorbidities [9,18,20,22,25]. In our study, most of the test population (patients with a minimum of 1 PIM)
have 3 comorbidities. We also observed that patients having 2 or ≥3 comorbidities have a significantly
higher risk when compared to the patients with no comorbidities but was not statistically significant as the pvalue is not less than 0.05.
We found that patients with asthma, thyroid, chronic liver disease, and COPD may have a lesser risk of
causing PIMs. This can be explained by the fact that drugs used as first-line therapy for these diseases are
not included as PIMs in updates 2019 AGS Beers Criteria.
Whereas cerebrovascular disease, acute kidney disease, hypertension, cardiovascular, and type 2 diabetes
mellitus were observed to have more risk of causing PIMs in this study population, justifiable with an odds
ratio greater than 1, although not statistically significant as the p-value was not less than 0.05. A study
carried out in the Arab population using bivariate regression analysis found PIM use to be more likely in
patients with comorbidities like diabetes, CVD, CKD, osteoarthritis, osteoporosis, and anxiety [9]. As this
study population includes ambulatory care patients, comorbidities like osteoporosis, osteoarthritis, anxiety
30

were observed to be more. Drug therapy for these conditions include antipsychotics, NSAIDs which are
PIMs as per updated 2019 AGS Beers Criteria.
Hypertension was observed to be the most common comorbidity in the control as well as the test group.
Anti-hypertensives used as PIMs were diuretics, prescribed mostly as combinations of one loop or thiazide
diuretic with one potassium-sparing diuretic and Prazosin. Other antihypertensive drugs are not included in
the PIM list as per updated 2019 AGS Beers Criteria which explains the high prevalence of Hypertension in
the control group as well. Type 2 diabetes mellitus was observed as the second most prevalent comorbidity
in both test and control group as most of the anti-diabetic drugs were not recognized as PIMs, but longacting sulphonylureas (included in updated 2019 AGS Beers Criteria)which were commonly prescribed
drugs for type 2 diabetes mellitus resulted in more odds of presence of a PIM.(Having a PIM)
The 2019 updated AGS Beers Criteria categorized PIMs into three types namely, drugs to be avoided, used
with caution, and drugs to be used with reduced dose. In our study, we found that the drugs to be used with
caution have high prevalence at 54% and the drugs to be avoided were 45% with reduce dose standing at
1%. A similar study done in Saudi Arabia revealed the prevalence of drugs to be avoided was more than the
drugs used with caution [9]. The study was done in an ambulatory care setting where most of the drugs used
were gastrointestinal agents which should be avoided in elderly patients. In our study, we observed that
gastrointestinal agents were given as per the rationale (which is <8weeks).
A study in India done in the cardiac OPD of a tertiary care hospital to evaluate PIM found that
Spironolactone was the most used PIM in the elderly patients [24]. In our study, it was found that diuretics
were the second most used PIM amongst elderly patients as diuretics are the most common drugs used in
heart failure patients. In other studies, NSAIDs and antipsychotics were the most prevalent PIMs to be used
in the geriatric population [15,9,17] as these studies have taken the patient population from ambulatory care
and mostly involve anxiety and osteoarthritis.
Elderly patients with medication history 3 or more drugs had a higher odds of having PIMs (OR:2.836, pvalue:0.012). Higher number of drugs in medication history can be due to the presence of co-morbidities
which have been identified as a risk factor for having PIMs. Therefore, higher number of drugs in
medication history can be indirectly linked to the prevalence of PIMs.
Significant amount of research consistently states polypharmacy as a major risk factor for PIMs
[4,5,9,16,17,23]. In this study, the total number of discharge drugs was categorized into three groups 03drugs, 4-7drugs, and >7 drugs. Elderly patients with >7drugs were more prevalent and at highest odds of
having PIMs (OR:31.875, p-value:0.00) followed by 4-7drugs (OR:5.988, p-value: 0.002).
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Possible risk of developing DDIs due to inappropriate medication use was also identified in this study. We
observed the test group to have a higher risk of serious (OR:19.06), moderate (OR:11.50) DDIs.
The role of caregivers including prescribers and clinical pharmacists should scale up, accommodating
necessary measures to manage elderly patients. Providing better healthcare by minimizing PIM use, in turn,
minimizing the related adverse events and improving the quality of life is essential.
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LIMITATIONS
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LIMITATIONS
•
•

•
•
•

Bodyweight in most of the subjects was not recorded as this study was conducted in the geriatric
population, where majority of the patients were unable to stand.
Medication history, personal and social history of the subjects like diet, history of smoking and
alcohol consumption was not available for all the patients in the patient records which led to a lot of
missing data.
Most of the time, when the patients did not get their current medications to hospital, he/she is
recorded to have no medication history.
Creatinine clearance levels were not available in all CKD patients.
ADR because of PIM was not recorded as the study was retrospective in nature.
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CONCLUSION
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CONCLUSION
Potentially inappropriate medication use poses a sizable health safety hazard in elderly. After evaluating the
potentially inappropriate medications of elderly patients using the updated Beers Criteria 2019. Prevalence
of PIMs that should be used with caution (54%) was found to be highest followed by PIMs to be avoided
(45%) and recommendation for reduce dose to be (1%).
Elderly patients with polypharmacy and higher age are at more odds to have PIMs. Similarly, patients with a
history of ≥3 drugs are at higher risk to have PIMs. Furthermore, we observed that patients with PIMs are at
higher risk of having serious and moderate DDIs.
A significant increase in the older population and the need to reduce preventable harm calls for more
multidisciplinary strategies to account for the use of high-risk medications. Prescribers can use this data to
determine patients at a higher risk for PIMs and be attentive to them while prescribing. Continuous
medication and prescription review done by a clinical pharmacist can aid in reducing the occurrence of
PIMs.

.

36

FUTURE DIRECTIONS
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FUTURE DIRECTIONS:
•
•
•
•

Studies with a larger sample size should be carried out to investigate the justification for PIM use.
Studies to evaluate association between readmissions and PIMs.
Studies to evaluate the association between comorbidity and PIM association in a more elaborate
manner.
A prospective study on the comparison between PIMs and drug-drug interactions and PIMs leading
to ADRs.
.
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Appendix – II

CASE REPORT FORM
STUDY: Prevalence and factors influencing inappropriate
medication use in elderly patients – A retrospective study using
Beers criteria
Hospital No:
Age:
Weight:

IP. No:
Gender: M/F
BMI:

Date of admission:
Date of discharge:

Complaints on admission:

Medical history:

Medication history:

Personal history:
Diagnosis with comorbidities:

Lab data:
Serum creatinine:

Creatinine clearance:

44

Brand name Generic name Strength

Dose/Dosage Frequency Duration
form
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